Biovaxys Technology Corp Stock Return On Equity
| BVAXF Stock | USD 0.05 0.01 11.78% |
Biovaxys Technology Corp fundamentals help investors to digest information that contributes to Biovaxys Technology's financial success or failures. It also enables traders to predict the movement of Biovaxys OTC Stock. The fundamental analysis module provides a way to measure Biovaxys Technology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biovaxys Technology otc stock.
Biovaxys |
Biovaxys Technology Corp OTC Stock Return On Equity Analysis
Biovaxys Technology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Biovaxys Technology Return On Equity | -0.73 |
Most of Biovaxys Technology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biovaxys Technology Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Biovaxys Technology Corp has a Return On Equity of -0.7323. This is 96.94% lower than that of the Healthcare sector and 97.99% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 136.23% higher than that of the company.
Biovaxys Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biovaxys Technology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biovaxys Technology could also be used in its relative valuation, which is a method of valuing Biovaxys Technology by comparing valuation metrics of similar companies.Biovaxys Technology is currently under evaluation in return on equity category among its peers.
Biovaxys Fundamentals
| Return On Equity | -0.73 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 11.35 M | |||
| Shares Outstanding | 106.72 M | |||
| Shares Owned By Insiders | 18.94 % | |||
| Price To Earning | (4.32) X | |||
| Price To Book | 2.53 X | |||
| EBITDA | (6.44 M) | |||
| Net Income | (6.46 M) | |||
| Cash And Equivalents | 39.05 K | |||
| Current Ratio | 0.16 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (5.29 M) | |||
| Earnings Per Share | (0.05) X | |||
| Number Of Employees | 17 | |||
| Beta | -0.59 | |||
| Market Capitalization | 8.73 M | |||
| Total Asset | 8.5 M | |||
| Retained Earnings | (80 M) | |||
| Working Capital | 35 M | |||
| Current Asset | 37 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -7.8 | |||
| Net Asset | 8.5 M |
About Biovaxys Technology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biovaxys Technology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovaxys Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovaxys Technology Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.